Federica Bertini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Federica Bertini has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Luca Gonsalvi
Istituto di Chimica dei Composti OrganoMetallici (ICCOM) Consiglio Nazionale delle Ricerche (CNR) Via Madonna del Piano 10 50019 Sesto Fiorentino (Florence) Italy
7 shared publications - Maurizio Peruzzini
ICCOM-CNR, Institute of Chemistry of OrganoMetallic Compounds, National Research Council of Italy, Via Madonna del Piano 10, I-50019 Sesto Fiorentino, Firenze, Italy
7 shared publications Irene Mellone
Consiglio Nazionale delle Ricerche (CNR), Istituto di Chimica dei Composti Organometallici (ICCOM), Via Madonna del Piano 10, 50019 Sesto Fiorentino (Firenze), Italy
5 shared publicationsAndreas W. Ehlers
Department of Chemistry and Pharmaceutical Sciences, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands
4 shared publicationsJ. Chris Slootweg
Department of Chemistry and Pharmaceutical Sciences, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands
4 shared publications- Alessio Giuseppe Morganti
Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy
3 shared publications
Latest Publications
- Open Access
- 10 September 2020
- Published by Wiley in Cancer Medicine
- Vol. 9 (21) , 7879-7887
Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case‐control study (PAULA‐1)
Conventionally fractionated chemoradiation (CRT) or chemotherapy (CHT) are considered as standard options in locally advanced pancreatic cancer (LAPC) while stereotactic body radiotherapy (SBRT) is an emerging treatment in this setting. The aim of this study was to compare two cohorts of LAPC patients treated with SBRT ± CHT vs CRT ± CHT in terms of local control (LC), distant metastases‐free survival (DMFS), progression‐free survival (PFS), overall survival (OS), and toxicity. Eighty patients were included. Patients in the two cohorts were matched according to: age ≤/>65 years, tumor diameter (two cut‐offs: </≥3.0 and </≥3.9 cm), clinical tumor stage and clinical nodal stage, neoadjuvant CHT, and adjuvant CHT. Median prescribed total dose was 30.0 Gy (range: 18.0‐37.5) and 54.0 Gy (18.0‐63.0) in SBRT and CRT cohorts, respectively. Toxicity was evaluated by CTCAE v4.0 scale. Survival curves were calculated by Kaplan‐Meier method. For hypothesis testing an equivalence and a non‐inferiority test was calculated. No statistically significant differences in terms of acute and late toxicity, DMFS, PFS, and OS were recorded among the two cohorts. Median, 1‐, and 2‐year LC was: 16.0 months, 53.1%, and 40.5% in the CRT cohort and 22.0 months, 80.4%, and 49.8% in the SBRT cohort, respectively (P: .017). A statistically non‐inferiority significance was recorded in terms of OS between CRT and SBRT (P = .031). Patients treated with SBRT showed higher LC rate and similar OS compared to CRT. Therefore, the design of confirmatory randomized studies comparing SBRT and CRT seems justified.
- 10 September 2020
- Published by Wiley in Cancer Medicine
- Vol. 9 (21) , 7879-7887
Open AccessStereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case‐control study (PAULA‐1)
Conventionally fractionated chemoradiation (CRT) or chemotherapy (CHT) are considered as standard options in locally advanced pancreatic cancer (LAPC) while stereotactic body radiotherapy (SBRT) is an emerging treatment in this setting. The aim of this study was to compare two cohorts of LAPC patients treated with SBRT ± CHT vs CRT ± CHT in terms of local control (LC), distant metastases‐free survival (DMFS), progression‐free survival (PFS), overall survival (OS), and toxicity. Eighty patients were included. Patients in the two cohorts were matched according to: age ≤/>65 years, tumor diameter (two cut‐offs: </≥3.0 and </≥3.9 cm), clinical tumor stage and clinical nodal stage, neoadjuvant CHT, and adjuvant CHT. Median prescribed total dose was 30.0 Gy (range: 18.0‐37.5) and 54.0 Gy (18.0‐63.0) in SBRT and CRT cohorts, respectively. Toxicity was evaluated by CTCAE v4.0 scale. Survival curves were calculated by Kaplan‐Meier method. For hypothesis testing an equivalence and a non‐inferiority test was calculated. No statistically significant differences in terms of acute and late toxicity, DMFS, PFS, and OS were recorded among the two cohorts. Median, 1‐, and 2‐year LC was: 16.0 months, 53.1%, and 40.5% in the CRT cohort and 22.0 months, 80.4%, and 49.8% in the SBRT cohort, respectively (P: .017). A statistically non‐inferiority significance was recorded in terms of OS between CRT and SBRT (P = .031). Patients treated with SBRT showed higher LC rate and similar OS compared to CRT. Therefore, the design of confirmatory randomized studies comparing SBRT and CRT seems justified.
- Open Access
- 11 June 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-10
Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival
To evaluate the impact of radiation dose on overall survival (OS) in patients treated with adjuvant chemoradiation (CRT) for pancreatic ductal adenocarcinoma (PDAC). A multicenter retrospective analysis on 514 patients with PDAC (T1–4; N0–1; M0) treated with surgical resection with macroscopically negative margins (R0–1) followed by adjuvant CRT was performed. Patients were stratified into 4 groups based on radiotherapy doses (group 1: < 45 Gy, group 2: ≥ 45 and < 50 Gy, group 3: ≥ 50 and < 55 Gy, group 4: ≥ 55 Gy). Adjuvant chemotherapy was prescribed to 141 patients. Survival functions were plotted using the Kaplan-Meier method and compared through the log-rank test. Median follow-up was 35 months (range: 3–120 months). At univariate analysis, a worse OS was recorded in patients with higher preoperative Ca 19.9 levels (≥ 90 U/ml; p < 0.001), higher tumor grade (G3–4, p = 0.004), R1 resection (p = 0.004), higher pT stage (pT3–4, p = 0.002) and positive nodes (p < 0.001). Furthermore, patients receiving increasing doses of CRT showed a significantly improved OS. In groups 1, 2, 3, and 4, median OS was 13.0 months, 21.0 months, 22.0 months, and 28.0 months, respectively (p = 0.004). The significant impact of higher dose was confirmed by multivariate analysis. Increasing doses of CRT seems to favorably impact on OS in adjuvant setting. The conflicting results of randomized trials on adjuvant CRT in PDAC could be due to < 45 Gy dose generally used.
- 11 June 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-10
Open AccessAdjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival
To evaluate the impact of radiation dose on overall survival (OS) in patients treated with adjuvant chemoradiation (CRT) for pancreatic ductal adenocarcinoma (PDAC). A multicenter retrospective analysis on 514 patients with PDAC (T1–4; N0–1; M0) treated with surgical resection with macroscopically negative margins (R0–1) followed by adjuvant CRT was performed. Patients were stratified into 4 groups based on radiotherapy doses (group 1: < 45 Gy, group 2: ≥ 45 and < 50 Gy, group 3: ≥ 50 and < 55 Gy, group 4: ≥ 55 Gy). Adjuvant chemotherapy was prescribed to 141 patients. Survival functions were plotted using the Kaplan-Meier method and compared through the log-rank test. Median follow-up was 35 months (range: 3–120 months). At univariate analysis, a worse OS was recorded in patients with higher preoperative Ca 19.9 levels (≥ 90 U/ml; p < 0.001), higher tumor grade (G3–4, p = 0.004), R1 resection (p = 0.004), higher pT stage (pT3–4, p = 0.002) and positive nodes (p < 0.001). Furthermore, patients receiving increasing doses of CRT showed a significantly improved OS. In groups 1, 2, 3, and 4, median OS was 13.0 months, 21.0 months, 22.0 months, and 28.0 months, respectively (p = 0.004). The significant impact of higher dose was confirmed by multivariate analysis. Increasing doses of CRT seems to favorably impact on OS in adjuvant setting. The conflicting results of randomized trials on adjuvant CRT in PDAC could be due to < 45 Gy dose generally used.
- Open Access
- 4 May 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 8 (7) , 5024-5029
Carbon dioxide hydrogenation catalysed by well-defined Mn(i) PNP pincer hydride complexes
Mn(i) PNP pincer hydride complexes were shown for the first time to catalyse the hydrogenation of CO2 to formate reaching quantitative yields and high TONs.
- 4 May 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 8 (7) , 5024-5029
Open AccessCarbon dioxide hydrogenation catalysed by well-defined Mn(i) PNP pincer hydride complexes
Mn(i) PNP pincer hydride complexes were shown for the first time to catalyse the hydrogenation of CO2 to formate reaching quantitative yields and high TONs.
- 22 September 2016
- Published by American Chemical Society (ACS) in Organometallics
- Vol. 35 (19) , 3344-3349
Selective Formic Acid Dehydrogenation Catalyzed by Fe-PNP Pincer Complexes Based on the 2,6-Diaminopyridine Scaffold
- 22 September 2016
- Published by American Chemical Society (ACS) in Organometallics
- Vol. 35 (19) , 3344-3349
Selective Formic Acid Dehydrogenation Catalyzed by Fe-PNP Pincer Complexes Based on the 2,6-Diaminopyridine Scaffold
- 28 June 2016
- Published by Royal Society of Chemistry (RSC) in Catalysis Science & Technology
- Vol. 6 (17) , 6504-6512
An active, stable and recyclable Ru( ii ) tetraphosphine-based catalytic system for hydrogen production by selective formic acid dehydrogenation
Well-defined and in situ made Ru(II) complexes of the linear tetraphosphine ligand meso-1,1,4,7,10,10-hexaphenyl-1,4,7,10-tetraphosphadecane (tetraphos-1, P4) proved to be effective catalysts for selective formic acid dehydrogenation with good yields and TONs in the presence of an added amine, both under batch and continuous feed experimental conditions. The mechanism was studied by solution NMR and DFT calculations, highlighting the role of the trans-dihydrido complex [Ru(H)2(meso-P4)] as the active species in catalysis.
- 28 June 2016
- Published by Royal Society of Chemistry (RSC) in Catalysis Science & Technology
- Vol. 6 (17) , 6504-6512
An active, stable and recyclable Ru( ii ) tetraphosphine-based catalytic system for hydrogen production by selective formic acid dehydrogenation
Well-defined and in situ made Ru(II) complexes of the linear tetraphosphine ligand meso-1,1,4,7,10,10-hexaphenyl-1,4,7,10-tetraphosphadecane (tetraphos-1, P4) proved to be effective catalysts for selective formic acid dehydrogenation with good yields and TONs in the presence of an added amine, both under batch and continuous feed experimental conditions. The mechanism was studied by solution NMR and DFT calculations, highlighting the role of the trans-dihydrido complex [Ru(H)2(meso-P4)] as the active species in catalysis.
- 6 April 2016
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 6 (5) , 2889-2893
Efficient and Mild Carbon Dioxide Hydrogenation to Formate Catalyzed by Fe(II) Hydrido Carbonyl Complexes Bearing 2,6-(Diaminopyridyl)diphosphine Pincer Ligands
- 6 April 2016
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 6 (5) , 2889-2893
Efficient and Mild Carbon Dioxide Hydrogenation to Formate Catalyzed by Fe(II) Hydrido Carbonyl Complexes Bearing 2,6-(Diaminopyridyl)diphosphine Pincer Ligands
- Open Access
- 1 June 2015
- Published by Swiss Chemical Society in Chimia
- Vol. 69 (6) , 331-8
New Wind in Old Sails: Novel Applications of Triphos-based Transition Metal Complexes as Homogeneous Catalysts for Small Molecules and Renewables Activation
Recent developments in the coordination chemistry and applications of Ru-triphos [triphos = 1,1,1-tris-(diphenylphosphinomethyl)ethane] systems are reviewed, highlighting their role as active and selective homogenous catalysts for small molecule activation, biomass conversions and in carbon dioxide utilization-related processes.
- 1 June 2015
- Published by Swiss Chemical Society in Chimia
- Vol. 69 (6) , 331-8
Open AccessNew Wind in Old Sails: Novel Applications of Triphos-based Transition Metal Complexes as Homogeneous Catalysts for Small Molecules and Renewables Activation
Recent developments in the coordination chemistry and applications of Ru-triphos [triphos = 1,1,1-tris-(diphenylphosphinomethyl)ethane] systems are reviewed, highlighting their role as active and selective homogenous catalysts for small molecule activation, biomass conversions and in carbon dioxide utilization-related processes.
- 13 January 2015
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 5 (2) , 1254-1265
Iron(II) Complexes of the Linear rac-Tetraphos-1 Ligand as Efficient Homogeneous Catalysts for Sodium Bicarbonate Hydrogenation and Formic Acid Dehydrogenation
- 13 January 2015
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 5 (2) , 1254-1265
Iron(II) Complexes of the Linear rac-Tetraphos-1 Ligand as Efficient Homogeneous Catalysts for Sodium Bicarbonate Hydrogenation and Formic Acid Dehydrogenation
- 25 November 2013
- Published by American Chemical Society (ACS) in Organometallics
- Vol. 32 (23) , 7053-7064
Inner- versus Outer-Sphere Ru-Catalyzed Formic Acid Dehydrogenation: A Computational Study
- 25 November 2013
- Published by American Chemical Society (ACS) in Organometallics
- Vol. 32 (23) , 7053-7064
Inner- versus Outer-Sphere Ru-Catalyzed Formic Acid Dehydrogenation: A Computational Study